STUDY OBJECTIVE: To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. DESIGN: Retrospective matched cohort. SETTING: Large academic medical center. PATIENTS: Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. MEASUREMENTS AND MAIN RESULTS: A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin-tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. CONCLUSIONS: The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.
STUDY OBJECTIVE: To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. DESIGN: Retrospective matched cohort. SETTING: Large academic medical center. PATIENTS: Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. MEASUREMENTS AND MAIN RESULTS: A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin-tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. CONCLUSIONS: The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.
Authors: Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Zachary C Dietch; Rhett N Willis; Puja M Shah; Robert G Sawyer Journal: Surg Infect (Larchmt) Date: 2015-10-20 Impact factor: 2.150
Authors: W Cliff Rutter; Jessica N Cox; Craig A Martin; Donna R Burgess; David S Burgess Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Ilse van Langeveld; Robin C Gagnon; Peggie F Conrad; Richard L Gamelli; Brendan Martin; Mashkoor A Choudhry; Michael J Mosier Journal: J Burn Care Res Date: 2017 Mar/Apr Impact factor: 1.845